CEO at Binding Site
Charles has been CEO of Birmingham based Binding Site Group since 2010. Employing 600 people, 400 in UK, the company is committed to the research, development, manufacture and distribution of immunodiagnostic serum protein assays. With extensive expertise in antibody specificity technology, Binding Site gives clinicians and laboratory staff tools to improve diagnosis and management of patients across a range of B-cell cancers and immune system disorders. The company has been awarded three Queen’s Awards for innovation and export.
Charles has worked in the diagnostic industry for more than 20 years, having previously been CEO of London-quoted Genetix Group, a very successful life science/diagnostics company that was acquired by Danaher Corporation. Prior to joining Genetix, Charles spent 14 years at Abbott Laboratories’ Diagnostic Division, where he held a number of senior commercial management positions in Europe and Asia Pacific.